The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 501–600 of 1,056
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
Ricciardi, C. A., & Gnudi, L. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154890 · Cited by 190
Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma
Huang, S.-P., Wu, M.-S., Shun, C.-T., Wang, H.-P., Lin, M.-T., Kuo, M.-L., & Lin, J.-T. (2004) · Journal of Biomedical Science · doi:10.1007/bf02256101 · Cited by 190
Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice
Matsui, T., Kanai-Azuma, M., Hara, K., Matoba, S., Hiramatsu, R., Kawakami, H., Kurohmaru, M., Koopman, P., & Kanai, Y. (2006) · Journal of Cell Science · doi:10.1242/jcs.03081 · Cited by 190
Wang, L., Fan, H., Zhang, Z.-Y., Lou, A.-J., Pei, G.-X., Jiang, S., Mu, T.-W., Qin, J.-J., Chen, S.-Y., & Jin, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.036 · Cited by 196
“Invitro and invivo studieshavedemonstrated thatVEGFcanpromote endothelial cell survival, proliferation, migration, and vascularization during endochondral bone formation [46,47].”
BackgroundRNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Kaiser, P. K., Symons, R. C. A., Shah, S. M., Quinlan, E. J., Tabandeh, H., Do, D. V., Reisen, G., Lockridge, J. A., Short, B., Guerciolini, R., et al. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.02.006 · Cited by 195
Gerber, S. A., Rybalko, V. Y., Bigelow, C. E., Lugade, A. A., Foster, T. H., Frelinger, J. G., & Lord, E. M. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051222 · Cited by 197
Hiratsuka, S., Goel, S., Kamoun, W. S., Maru, Y., Fukumura, D., Duda, D. G., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100446108 · Cited by 196
Kong, D., Li, Y., Wang, Z., Banerjee, S., & Sarkar, F. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4277 · Cited by 195
RetractedOverexpression of VEGF-A in podocytes of adult mice causes glomerular disease
Veron, D., Reidy, K. J., Bertuccio, C., Teichman, J., Villegas, G., Jimenez, J., Shen, W., Kopp, J. B., Thomas, D. B., & Tufro, A. (2010) · Kidney International · doi:10.1038/ki.2010.64 · Cited by 197
Cao, L., Wang, J., Hou, J., Xing, W., & Liu, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.005 · Cited by 197
Silk as a potential candidate for bone tissue engineering
Mottaghitalab, F., Hosseinkhani, H., Shokrgozar, M. A., Mao, C., Yang, M., & Farokhi, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.031 · Cited by 190
RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock
Mikelis, C. M., Simaan, M., Ando, K., Fukuhara, S., Sakurai, A., Amornphimoltham, P., Masedunskas, A., Weigert, R., Chavakis, T., Adams, R. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7725 · Cited by 192
Gu, J.-W., Makey, K. L., Tucker, K. B., Chinchar, E., Mao, X., Pei, I., Thomas, E. Y., & Miele, L. (2013) · Vascular Cell · doi:10.1186/2045-824x-5-9 · Cited by 189
Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer
Kamat, A. A., Merritt, W. M., Coffey, D., Lin, Y. G., Patel, P. R., Broaddus, R., Nugent, E., Han, L. Y., Landen, C. N., Spannuth, W. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1017 · Cited by 192
Preeclampsia: Pathophysiology and management
Nirupama, R., Divyashree, S., Janhavi, P., Muthukumar, S. P., & Ravindra, P. V. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2020.101975 · Cited by 160
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13009 · Cited by 189
Signaling Pathways Governing Tumor Angiogenesis
Sakurai, T., & Kudo, M. (2011) · Oncology · doi:10.1159/000333256 · Cited by 190
Park, K. M., & Gerecht, S. (2014) · Nature Communications · doi:10.1038/ncomms5075 · Cited by 185
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer
Zhang, G., Kodani, S., & Hammock, B. D. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.11.003 · Cited by 185
“Most anti-angiogenic drugs on the market target VEGFR2/VEGF pathway to inhibit angiogenesis.”
BackgroundInfluentialBajaj, S., Asati, V., Singh, J., & Roy, P. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.051 · Cited by 187
VEGF and FGF-2: Promising targets for the treatment of respiratory disorders
Laddha, A. P., & Kulkarni, Y. A. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.08.003 · Cited by 187
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Gressett, S. M., & Shah, S. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l426 · Cited by 187
Sopher, B. L., Thomas, P. S., LaFevre-Bernt, M. A., Holm, I. E., Wilke, S. A., Ware, C. B., Jin, L.-W., Libby, R. T., Ellerby, L. M., & La Spada, A. R. (2004) · Neuron · doi:10.1016/s0896-6273(04)00082-0 · Cited by 191
“The initial evi164/5, VEGF 188/9, and -/VEGF206 (Ferrara et al., 2003). dence for this emerging view came from an unexpected We began by using a TaqMan probe and PCR primers finding of motor neuron disease in mice lacking just that spanned a portion of the VEGF gene included in all the HRE sequence…”
BackgroundMethodVlahakis, N. E., Young, B. A., Atakilit, A., & Sheppard, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412816200 · Cited by 191
The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
Mabeta, P., & Steenkamp, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415585 · Cited by 183
“On the other hand, VEGFR-2 is important for vasculogenesis and angiogenesis as it promotes both processes through several mechanisms [14,18].”
BackgroundInfluentialThibault, B., Castells, M., Delord, J.-P., & Couderc, B. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9456-2 · Cited by 184
“It enhances the proliferation and migration of endothelial cells as well as the permeability of existing vessels [66].”
BackgroundPharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors
Lee, K., Jeong, K.-W., Lee, Y., Song, J. Y., Kim, M. S., Lee, G. S., & Kim, Y. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.002 · Cited by 187
Pathophysiological Basis for the Formation of the Tumor Microenvironment
Horsman, M. R., & Vaupel, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00066 · Cited by 189
“This process begins with the release of angiogenic factors, primarily vascular endothelial growth factor (VEGF), by the tumor cells (5).”
BackgroundCovalent Growth Factor Immobilization Strategies for Tissue Repair and Regeneration
Masters, K. S. (2011) · Macromolecular Bioscience · doi:10.1002/mabi.201000505 · Cited by 184
Toward the biomimetic implant surface: Biopolymers on titanium-based implants for bone regeneration
Tejero, R., Anitua, E., & Orive, G. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.01.001 · Cited by 187
On the cytokines produced by human neutrophils in tumors
Tecchio, C., Scapini, P., Pizzolo, G., & Cassatella, M. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.004 · Cited by 188
Chrzanowska-Wodnicka, M., Kraus, A. E., Gale, D., White, G. C., & VanSluys, J. (2008) · Blood · doi:10.1182/blood-2007-08-109710 · Cited by 186
Xia, L., Lin, K., Jiang, X., Fang, B., Xu, Y., Liu, J., Zeng, D., Zhang, M., Zhang, X., Chang, J., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.028 · Cited by 190
“VEGF has been widely reported as a key angiogenic factor with the strongest and most significant biological activity in enhancing blood formation [40].”
BackgroundInflammatory and angiogenic biomarkers in diabetic retinopathy
Kaštelan, S., Orešković, I., Bišćan, F., Kaštelan, H., & Gverović Antunica, A. (2020) · Biochemia medica · doi:10.11613/bm.2020.030502 · Cited by 178
“The VEGF family consists of six proteins: VEGF-A,-B,-C,-D,-E, and placental growth factor (PGF) with VEGF-A being the best known and most widely used in clinical practice (80).”
BackgroundThe Impact of Hypoxia in Early Pregnancy on Placental Cells
Zhao, H., Wong, R. J., & Stevenson, D. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189675 · Cited by 171
Guidance of vascular and neural network formation
Eichmann, A., Noble, F. L., Autiero, M., & Carmeliet, P. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.01.008 · Cited by 186
Pillozzi, S., Brizzi, M. F., Bernabei, P. A., Bartolozzi, B., Caporale, R., Basile, V., Boddi, V., Pegoraro, L., Becchetti, A., & Arcangeli, A. (2007) · Blood · doi:10.1182/blood-2006-02-003772 · Cited by 187
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
Contribution of adipose tissue to development of cancer
Cozzo, A. J., Fuller, A. M., & Makowski, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170008 · Cited by 188
“Among these, the VEGF/VEGFR system— one of the best characterized and most potent of the known proangiogenic signaling pathways—is the main mediator of angiogenic activity in adipose tissue (115, 166, 225).”
PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR IN SEVERE SEPSIS
van der Flier, M., van Leeuwen, H. J., van Kessel, K. P., Kimpen, J. L., Hoepelman, A. I., & Geelen, S. P. (2005) · Shock · doi:10.1097/01.shk.0000150728.91155.41 · Cited by 185
“In addition, hypoxia increases VEGF production via hypoxia-inducible factor-1a transcription factor (3).”
BackgroundAngiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension
Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., & Deray, G. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.025 · Cited by 186
Mechanisms of resistance to antiangiogenesis therapy
Azam, F., Mehta, S., & Harris, A. L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.020 · Cited by 178
Zhu, C.-Q., Shih, W., Ling, C.-H., & Tsao, M.-S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.031351 · Cited by 187
Ewan, L. C., Jopling, H. M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G. J., Walker, J. H., Zachary, I. C., & Ponnambalam, S. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00462.x · Cited by 183
“Alternative splicing of the VEGF-A RNA transcript can produce at least six different protein isoforms, of which the VEGF-A165 isoform is the major proangiogenic factor secreted by many human tissues and tumors (2,6,7).”
BackgroundInteraction between Bevacizumab and Murine VEGF-A: A Reassessment
Yu, L., Wu, X., Cheng, Z., Lee, C. V., LeCouter, J., Campa, C., Fuh, G., Lowman, H., & Ferrara, N. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1175 · Cited by 180
“One of the key mediators of physiological and pathologic angiogenesis is vascular endothelial growth factor (VEGF)-A.(5) Early studies show that VEGF-A is increased in the eye fluids of patients with ischemic retinal disorders(6) or in neovascular membranes of patients with age-related macular degeneration (AMD).”
BackgroundSelf-citationHu, X., Neoh, K.-G., Shi, Z., Kang, E.-T., Poh, C., & Wang, W. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.006 · Cited by 182
Clayton, J. A., Chalothorn, D., & Faber, J. E. (2008) · Circulation Research · doi:10.1161/circresaha.108.181115 · Cited by 188
Carlsson, L., Clarke, J. C., Yen, C., Gregoire, F., Albery, T., Billger, M., Egnell, A.-C., Gan, L.-M., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 178
“This is an open access article under the CC BY-NC-ND license (http new blood vessel formation, has a pro-survival effect on vascular, endothelial, and cardiac cells, and enhances endothelial proliferation from epicardial-derived progenitor cells (for review, see Ferrara et al.9).9–11 However, while a variety of approa…”
BackgroundTissue remodelling through branching morphogenesis
Affolter, M., Zeller, R., & Caussinus, E. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2797 · Cited by 185
Therapeutic angiogenesis and vasculogenesis for tissue regeneration
Madeddu, P. (2005) · Experimental Physiology · doi:10.1113/expphysiol.2004.028571 · Cited by 185
“By interacting with endothelial tyrosine kinase VEGF receptors VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR), VEGF-A regulates the progression phase of angiogenesis and induces ECs to proliferate, migrate and survive (Ferrara & Devis-Smyth, 1997; Ferrara, 2003).”
BackgroundStevenson, W., Cheng, S.-F., Dastjerdi, M. H., Ferrari, G., & Dana, R. (2012) · The Ocular Surface · doi:10.1016/j.jtos.2012.01.005 · Cited by 179
Pazopanib: Clinical development of a potent anti-angiogenic drug
Schutz, F. A. B., Choueiri, T. K., & Sternberg, C. N. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.02.012 · Cited by 183
Propranolol for complicated infantile haemangiomas: a case series of 30 infants: Correspondence
Manunza, F., Syed, S., Laguda, B., Linward, J., Kennedy, H., Gholam, K., Glover, M., Giardini, A., & Harper, J. I. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09597.x · Cited by 187
Nonclassic Endogenous Novel Regulators of Angiogenesis
Ribatti, D., Conconi, M. T., & Nussdorfer, G. G. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.3 · Cited by 178
“VEGF and VEGF Rs are the first ECspecific signal transduction pathway activated during vascular development and are critical molecules in the formation of the vascular system, as evidenced in embryos homozygous and heterozygous for a targeted null mutation in their genes (Ferrara et al., 2003).”
BackgroundHeat Shock Proteins Regulatory Role in Neurodevelopment
Miller, D. J., & Fort, P. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00821 · Cited by 175
“One such factor is vascular endothelial growth factor A (VEGF-A), an endothelial cell-specific mitogen and potent agonist of angiogenesis (Kim et al., 1993; Ferrara et al., 2003).”
Biological significance of c-erbB family oncogenes in head and neck cancer
Rogers, S. J., Harrington, K. J., Rhys-Evans, P., O-Charoenrat, P., & Eccles, S. A. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5047-1 · Cited by 186
“Neoangiogenesis and its potential for therapeutic intervention have recently been extensively reviewed [98,99].”
BackgroundStarzec, A., Vassy, R., Martin, A., Lecouvey, M., Di Benedetto, M., Crépin, M., & Perret, G. Y. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.08.005 · Cited by 167
Lin, E. Y., Li, J.-F., Bricard, G., Wang, W., Deng, Y., Sellers, R., Porcelli, S. A., & Pollard, J. W. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.10.003 · Cited by 168
Dehghani, S., Nosrati, R., Yousefi, M., Nezami, A., Soltani, F., Taghdisi, S. M., Abnous, K., Alibolandi, M., & Ramezani, M. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.03.037 · Cited by 181
Nelson, C. M., Pirone, D. M., Tan, J. L., & Chen, C. S. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-10-0745 · Cited by 180
“VEGF has a central role in regulating vascular permeability and angiogenesis (Ferrara et al., 2003), and thus an understanding of its ability to regulate the cadherin-and integrin-based adhesion systems is an important avenue of study.”
BackgroundSwimming Training in Rats Increases Cardiac MicroRNA-126 Expression and Angiogenesis
DA SILVA, N. D., FERNANDES, T., SOCI, U. P. R., MONTEIRO, A. W. A., PHILLIPS, M. I., & DE OLIVEIRA, E. M. (2012) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31824e8a36 · Cited by 179
Duan, Yu, Y., Yu, Y., Li, Y., Wang, J., Geng, W., Jiang, L., Li, Q., Zhou, X., & Sun, Z. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s71074 · Cited by 180
“migration, and vascular permeability.(41) Results from the Western blot analysis confirmed that the Nano-SiO 2 induced endothelial cell dysfunction, as well as activated autophagy (Figure 8).”
BackgroundMesenchymal stem cells and neovascularization: role of platelet‐derived growth factor receptors
Ball, S. G., Shuttleworth, C. A., & Kielty, C. M. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00120.x · Cited by 178
“A variety of different cell types express VEGF-A, including macrophages, vascular SMC, numerous tumour cells and MSC [5, 17, 18].”
BackgroundThe Hydrogen Sulfide Donor NaHS Promotes Angiogenesis in a Rat Model of Hind Limb Ischemia
Wang, M.-J., Cai, W.-J., Li, N., Ding, Y.-J., Chen, Y., & Zhu, Y.-C. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2945 · Cited by 184
“VEGFR2 is the main receptor type to mediate the pro-angiogenic effect of VEGF (10), while VEGFR2 activation is insufficient in ischemic conditions (26).”
Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells
Sulpice, E., Ding, S., Muscatelli‐Groux, B., Bergé, M., Han, Z. C., Plouet, J., Tobelem, G., & Merkulova‐Rainon, T. (2009) · Biology of the Cell · doi:10.1042/bc20080221 · Cited by 178
“VEGF-A binds to two structurally related RTKs (receptor tyrosine kinases): VEGFR-1 [VEGF receptor-1; Flt-1 (fms-like tyrosine kinase 1)] and VEGFR-2 [KDR (kinase insert domain-containing receptor); Flk-1 (fetal liver kinase 1)] (Ferrara et al., 2003).”
BackgroundSantel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Durieux, B., Löffler, K., Fechtner, M., Röhl, T., Fisch, G., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302778 · Cited by 183
Gene Therapy for Parkinson’s Disease, An Update
Axelsen, T. M., & Woldbye, D. P. D. (2018) · Journal of Parkinson's Disease · doi:10.3233/jpd-181331 · Cited by 170
“The VEGF family of proteins consists of VEGF-A VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PLGF), with VEGF-A, and to some extent VEGF-B, being the most physiologically active [131].”
BackgroundWong, C., & Jin, Z.-G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503198200 · Cited by 176
Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity
Lepore, D., Quinn, G. E., Molle, F., Baldascino, A., Orazi, L., Sammartino, M., Purcaro, V., Giannantonio, C., Papacci, P., & Romagnoli, C. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.015 · Cited by 184
Boss, D. S., Glen, H., Beijnen, J. H., Keesen, M., Morrison, R., Tait, B., Copalu, W., Mazur, A., Wanders, J., O'Brien, J. P., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.154 · Cited by 183
“Vascular endothelial growth factor has been identified as a crucial regulator of physiological and pathological angiogenesis, primarily via activation of VEGF receptor-2 (VEGFR2; kinase insert domain receptor (KDR); Ferrara et al, 2003).”
Vascular endothelial growth factor biology: clinical implications for ocular treatments
Bhisitkul, R. B. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.098426 · Cited by 181
Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
Konopleva, M., Tabe, Y., Zeng, Z., & Andreeff, M. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.06.001 · Cited by 178
ANRIL: A Regulator of VEGF in Diabetic Retinopathy
Thomas, A. A., Feng, B., & Chakrabarti, S. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-20569 · Cited by 181
Advances in On-Chip Vascularization
Haase, K., & Kamm, R. D. (2017) · Regenerative Medicine · doi:10.2217/rme-2016-0152 · Cited by 173
Robinson, C. J., Mulloy, B., Gallagher, J. T., & Stringer, S. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510760200 · Cited by 175
Fernandez, M., Mejias, M., Garcia-Pras, E., Mendez, R., Garcia-Pagan, J. C., & Bosch, J. (2007) · Hepatology · doi:10.1002/hep.21785 · Cited by 177
Redox regulation of protein kinases
Truong, T. H., & Carroll, K. S. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.790873 · Cited by 169
“This is a vital process involved in embryonic development, skeletal growth, wound repair, and reproductive functions (Ferrara et al., 2003).”
Inhaled Nitric Oxide Enhances Distal Lung Growth after Exposure to Hyperoxia in Neonatal Rats
Lin, Y.-J., Markham, N. E., Balasubramaniam, V., Tang, J.-R., Maxey, A., Kinsella, J. P., & Abman, S. H. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000163378.94837.3e · Cited by 180
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Georganaki, M., van Hooren, L., & Dimberg, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03081 · Cited by 172
Krueger, J., Liu, D., Scholz, K., Zimmer, A., Shi, Y., Klein, C., Siekmann, A., Schulte-Merker, S., Cudmore, M., Ahmed, A., et al. (2011) · Development · doi:10.1242/dev.063933 · Cited by 177
“Genetic studies in mice have shown that Flt1 plays a pivotal role in both developmental and pathological forms of angiogenesis (Ferrara et al., 2003; Fong et al., 1995).”
BackgroundVEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain
Le Bras, B., Barallobre, M.-J., Homman-Ludiye, J., Ny, A., Wyns, S., Tammela, T., Haiko, P., Karkkainen, M. J., Yuan, L., Muriel, M.-P., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1646 · Cited by 178
Targeting VEGF in eye neovascularization: What's new?
Amadio, M., Govoni, S., & Pascale, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.027 · Cited by 175
“In particlar, VEGF121 is fundamental for renal function [162] and it has een shown to protect rats from kidney infarction in thrombotic icroangiopathy through maintaining NO production and/or preenting EC death [163].”
BackgroundInfluentialWeng, L., Boda, S. K., Teusink, M. J., Shuler, F. D., Li, X., & Xie, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06521 · Cited by 181
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
“proangiogenic cytokine.(7) Thus, anti-VEGF and other antiangiogenic agents would seem to be attractive therapeutic strategies.”
BackgroundAcceleration of diabetic wound healing using a novel protease–anti-protease combination therapy
Gao, M., Nguyen, T. T., Suckow, M. A., Wolter, W. R., Gooyit, M., Mobashery, S., & Chang, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517847112 · Cited by 182
“Our results are in agreement with the increased VEGF levels seen in human wound fluid (35) and in epidermal keratinocytes (36).”
ResultPathophysiology, screening and treatment of ROP: A multi-disciplinary perspective
Chan-Ling, T., Gole, G. A., Quinn, G. E., Adamson, S. J., & Darlow, B. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.09.002 · Cited by 176
“VEGFC and D bind to VEGFR3, 822 which is the key regulator of lymphangiogenic activity.”
The Janus Face of VEGF in Stroke
Geiseler, S. J., & Morland, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051362 · Cited by 176
Lacal, P. M., & Graziani, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.023 · Cited by 177
Protein-based signaling systems in tissue engineering
Boontheekul, T., & Mooney, D. J. (2003) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2003.08.004 · Cited by 180
Vascular endothelial growth factor and related molecules in acute lung injury
Mura, M., dos Santos, C. C., Stewart, D., & Liu, M. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00202.2004 · Cited by 180
“Three VEGF receptors (VEGFRs) have been identified: VEGFR-1, VEGFR-2, and VEGFR-3 (43, 141).”
BackgroundInfluentialSun, Y., Jin, K., Childs, J. T., Xie, L., Mao, X. O., & Greenberg, D. A. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2005.10.016 · Cited by 178
“VEGFA binds to VEGFR1 with higher affinity than to VEGFR2, but the interaction with VEGFR2 elicits a greater increase in protein kinase activity, and the cytoproliferative activity of VEGFA appears to be attributable primarily to its effect on VEGFR2 (Ferrara et al., 2003).”
BackgroundVasculogenesis and Angiogenesis in the IUGR Placenta
Arroyo, J. A., & Winn, V. D. (2008) · Seminars in Perinatology · doi:10.1053/j.semperi.2008.02.006 · Cited by 167
Vascular Dysfunction in Preeclampsia
Brennan, L. J., Morton, J. S., & Davidge, S. T. (2014) · Microcirculation · doi:10.1111/micc.12079 · Cited by 158
“It promotes angiogenesis by binding to two receptor tyrosine kinases, VEGF receptor 1 and VEGF receptor 2 (reviewed in [44]).”
BackgroundZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
Ryan, A. J., & Wedge, S. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602603 · Cited by 177
“Significantly, activation of VEGFR-2 alone is necessary and sufficient to effect VEGF-induced mitogenesis, angiogenesis and vascular permeability (Ferrara et al, 2003).”
BackgroundInfluentialMonoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 176
Tiseo, M., Boni, L., Ambrosio, F., Camerini, A., Baldini, E., Cinieri, S., Brighenti, M., Zanelli, F., Defraia, E., Chiari, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4844 · Cited by 176
New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications
Wang, Y., Wang, L., Chen, C., & Chu, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0766-4 · Cited by 178
“The most predominant growth factor of angiogenesis is VEGF, consisting of VEGF-A/B/C/D and placental growth factor (PlGF) [16, 17].”
VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes
Halin, C., Tobler, N. E., Vigl, B., Brown, L. F., & Detmar, M. (2007) · Blood · doi:10.1182/blood-2007-01-066811 · Cited by 174
Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization
Kawamura, H., Li, X., Goishi, K., van Meeteren, L. A., Jakobsson, L., Cébe-Suarez, S., Shimizu, A., Edholm, D., Ballmer-Hofer, K., Kjellén, L., et al. (2008) · Blood · doi:10.1182/blood-2007-12-125856 · Cited by 171
Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation
Singleton, P. A., Lingen, M. W., Fekete, M. J., Garcia, J. G. N., & Moss, J. (2006) · Microvascular Research · doi:10.1016/j.mvr.2006.04.004 · Cited by 178
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.